Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Marx

Showing results (351-360 of 365) with videos related to

Pageof 37
Sort By:
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Journal of Neurotrauma|November 3, 2022
White Matter Microstructure Is Associated with Serum Neuroactive Steroids and Psychological FunctioningLisa F Umminger, Philine Rojczyk, Johanna Seitz-Holland, et al.
Circulation|March 18, 2026
Prognostic Factors for Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke: A Systematic Review and Meta-AnalysisFaizan Khan, Vignan Yogendrakumar, Ronda Lun, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target EngagementIsaac E Marx, Thomas A Dineen, Jessica Able, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
American Journal of Hematology|December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World StudyNilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Emerging Infectious Diseases|November 26, 2024
Bartonella quintana Infection in Kidney Transplant Recipients from Donor Experiencing Homelessness, United States, 2022Amy M Beeson, Shannan N Rich, Michael E Russo, et al.
Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Clinical Epigenetics|March 16, 2020
An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation lociMark W Logue, Mark W Miller, Erika J Wolf, et al.
Pageof 37

Showing results (351-360 of 365) with videos related to

Sort By:
Pageof 37
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Journal of Neurotrauma|November 3, 2022
White Matter Microstructure Is Associated with Serum Neuroactive Steroids and Psychological FunctioningLisa F Umminger, Philine Rojczyk, Johanna Seitz-Holland, et al.
Circulation|March 18, 2026
Prognostic Factors for Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke: A Systematic Review and Meta-AnalysisFaizan Khan, Vignan Yogendrakumar, Ronda Lun, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target EngagementIsaac E Marx, Thomas A Dineen, Jessica Able, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
American Journal of Hematology|December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World StudyNilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Emerging Infectious Diseases|November 26, 2024
Bartonella quintana Infection in Kidney Transplant Recipients from Donor Experiencing Homelessness, United States, 2022Amy M Beeson, Shannan N Rich, Michael E Russo, et al.
Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Clinical Epigenetics|March 16, 2020
An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation lociMark W Logue, Mark W Miller, Erika J Wolf, et al.
Pageof 37